Related Experiment Video

Updated: Mar 30, 2026

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

12.2K

Targeted Therapy for MAPK Alterations in Pediatric Gliomas

A Y Truong1, T P Nicolaides1

  • 1Department of Pediatrics and Neurosurgery University of California, San Francisco, CA, USA.

Brain Disorders & Therapy
|November 4, 2015
PubMed

Insights

Targeted therapies show promise for treating pediatric gliomas by addressing mutations in the mitogen-activated protein kinase (MAPK) pathway. This review details the biology, pre-clinical data, and clinical trials of these novel cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The mitogen-activated protein kinase (MAPK) pathway is crucial for normal cell development but is frequently implicated in cancer initiation and progression.
  • Mutations in key MAPK pathway proteins like RAS, RAF kinases, and MEK1/2 can drive tumorigenesis.
  • Understanding oncogenic mutations enables the development of targeted therapies for various cancers.

Purpose of the Study:

  • To review the history and development of targeted therapies for pediatric gliomas.
  • To elucidate the role of MAPK pathway mutations in pediatric glioma development.
  • To summarize pre-clinical and clinical data for MAPK-targeted therapies in this patient population.

Main Methods:

  • Literature review of pre-clinical studies and clinical trials.
  • Analysis of the biological mechanisms of MAPK pathway mutations in gliomas.
  • Synthesis of data on targeted therapy efficacy and safety.

Main Results:

  • Specific mutations in the MAPK pathway are identified as drivers in pediatric gliomas.
  • Pre-clinical studies demonstrate the potential of targeting these mutations.
  • Clinical trials are evaluating the efficacy of various targeted agents in pediatric glioma patients.

Conclusions:

  • Targeted therapies offer a promising avenue for treating pediatric gliomas by directly addressing oncogenic drivers.
  • Further research and clinical trials are essential to optimize these treatments for improved patient outcomes.
  • The understanding of MAPK pathway biology is critical for advancing precision medicine in pediatric oncology.
Keywords:
MAPKOncogenic mutationsPediatric gliomasTumorigenesis

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K